Show simple item record

dc.contributor.authorA Elnakady, Yasser
dc.contributor.authorChatterjee, Indranil
dc.contributor.authorBischoff, Markus
dc.contributor.authorRohde, Manfred
dc.contributor.authorJosten, Michaele
dc.contributor.authorSahl, Hans-Georg
dc.contributor.authorHerrmann, Mathias
dc.contributor.authorMüller, Rolf
dc.date.accessioned2016-03-09T15:48:40Zen
dc.date.available2016-03-09T15:48:40Zen
dc.date.issued2016en
dc.identifier.citationInvestigations to the Antibacterial Mechanism of Action of Kendomycin. 2016, 11 (1):e0146165 PLoS ONEen
dc.identifier.issn1932-6203en
dc.identifier.pmid26795276en
dc.identifier.doi10.1371/journal.pone.0146165en
dc.identifier.urihttp://hdl.handle.net/10033/601041en
dc.description.abstractThe emergence of bacteria that are resistant to many currently used drugs emphasizes the need to discover and develop new antibiotics that are effective against such multi-resistant strains. Kendomycin is a novel polyketide that has a unique quinone methide ansa structure and various biological properties. This compound exhibits strong antibacterial activity against Gram-negative and Gram-positive bacteria, including methicillin-resistant Staphylococcus aureus (MRSA). Despite the promise of kendomycinin in several therapeutic areas, its mode of action has yet to be identified.
dc.language.isoenen
dc.titleInvestigations to the Antibacterial Mechanism of Action of Kendomycin.en
dc.typeArticleen
dc.contributor.departmentHelmholtz Institute for Pharmaceutical Research Saarland, Helmholtz Centre for Infection Research and Department of Pharmaceutical Biotechnology, Saarland University, Saarbrücken, Germany.en
dc.identifier.journalPloS oneen
refterms.dateFOA2018-06-14T09:19:20Z
html.description.abstractThe emergence of bacteria that are resistant to many currently used drugs emphasizes the need to discover and develop new antibiotics that are effective against such multi-resistant strains. Kendomycin is a novel polyketide that has a unique quinone methide ansa structure and various biological properties. This compound exhibits strong antibacterial activity against Gram-negative and Gram-positive bacteria, including methicillin-resistant Staphylococcus aureus (MRSA). Despite the promise of kendomycinin in several therapeutic areas, its mode of action has yet to be identified.


Files in this item

Thumbnail
Name:
Elnakady et al.PDF
Size:
2.751Mb
Format:
PDF
Description:
Open Access publication

This item appears in the following Collection(s)

Show simple item record